Michael A. Kohanski

Michael A. Kohanski

Auto-generated profile, based on publicly available information

Michael A. Kohanski

Department of Otorhinolaryngology University of Pennsylvania Philadelphia Pennsylvania USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2021 in Science
Verified
Journal Article
Closed access
PDF file
ALAllison J. Lopatkin
Allison J. Lopatkin
SBSarah C. Bening
Sarah C. Bening
AMAbigail L. Manson
Abigail L. Manson
JSJonathan M. Stokes
Jonathan M. Stokes
MKMichael A. Kohanski
Michael A. Kohanski
JCJames J. Collins
James J. Collins
Although metabolism plays an active role in antibiotic lethality, antibiotic resistance is generally associated with drug target modification, enzymatic inactivation, and/or transport rather than metabolic processes. Evolution experiments of Escherichia coli rely on growth-dependent selection, which may provide a limited view of the antibiotic resistance landscape. We sequenced and analyzed E. coli adapted to representative antibiotics at increasingly heightened metabolic states. This revealed various underappreciated noncanonical genes, such as those related to central carbon and energy metabolism, which are implicated in antibiotic resistance. These metabolic alterations lead to lower basal respiration, which prevents antibiotic-mediated induction of tricarboxylic acid cycle activity, thus avoiding metabolic toxicity and minimizing drug lethality. Several of the identified metabolism-specific mutations are overrepresented in the genomes of >3500 clinical E. coli pathogens, indicating clinical relevance.

2 April 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
YLYize Li
Yize Li
DRDavid Michael Renner
David Michael Renner
CCCourtney E. Comar
Courtney E. Comar
JWJillian N. Whelan
Jillian N. Whelan
HRHanako M. Reyes
Hanako M. Reyes
Susan WeissSusan Weiss
Susan Weiss
Coronaviruses are adept at evading host antiviral pathways induced by viral double-stranded RNA, including interferon (IFN) signaling, oligoadenylate synthetase–ribonuclease L (OAS-RNase L), and protein kinase R (PKR). While dysregulated or inadequate IFN responses have been associated with severe coronavirus infection, the extent to which the recently emerged SARS-CoV-2 activates or antagonizes these pathways is relatively unknown. We found that SARS-CoV-2 infects patient-derived nasal epithelial cells, present at the initial site of infection; induced pluripotent stem cell-derived alveolar type 2 cells (iAT2), the major cell type infected in the lung; and cardiomyocytes (iCM), consistent with cardiovascular consequences of COVID-19 disease. Robust activation of IFN or OAS-RNase L is not observed in these cell types, whereas PKR activation is evident in iAT2 and iCM. In SARS-CoV-2–infected Calu-3 and A549 ACE2 lung-derived cell lines, IFN induction remains relatively weak; however, activation of OAS-RNase L and PKR is observed. This is in contrast to Middle East respiratory syndrome (MERS)-CoV, which effectively inhibits IFN signaling and OAS-RNase L and PKR pathways, but is similar to mutant MERS-CoV lacking innate immune antagonists. Remarkably, OAS-RNase L and PKR are activated in MAVS knockout A549 ACE2 cells, demonstrating that SARS-CoV-2 can induce these host antiviral pathways despite minimal IFN production. Moreover, increased replication and cytopathic effect in RNASEL knockout A549 ACE2 cells implicates OAS-RNase L in restricting SARS-CoV-2. Finally, while SARS-CoV-2 fails to antagonize these host defense pathways, which contrasts with other coronaviruses, the IFN signaling response is generally weak. These host–virus interactions may contribute to the unique pathogenesis of SARS-CoV-2.

11 July 2020 in International Forum of Allergy & Rhinology
Verified
Journal Article
Open access
PDF file
MKMichael A. Kohanski
Michael A. Kohanski
LLL. James Lo
L. James Lo
MWMichael S. Waring
Michael S. Waring
The coronavirus disease‐2019 (COVID‐19) pandemic has heightened the awareness of aerosol generation by human expiratory events and their potential role in viral respiratory disease transmission. Concerns over high severe acute respiratory syndrome‒coronavirus‐2 (SARS‐CoV‐2) viral burden of mucosal surfaces has raised questions about the aerosol‐generating potential and dangers of many otorhinolaryngologic procedures. However, the risks of aerosol generation and associated viral transmission by droplet or airborne routes for many otorhinolaryngology procedures are largely unknown. Indoor aerosol and droplet viral respiratory transmission risk is influenced by 4 factors: (1) aerosol or droplet properties; (2) indoor airflow; (3) virus‐specific factors; and (4) host‐specific factors. Herein we elaborate on known aerosol vs droplet properties, indoor airflow, and aerosol‐generating events to provide context for risks of aerosol infectious transmission. We also provide simple but typically effective measures for mitigating the spread and inhalation of viral aerosols in indoor settings. Understanding principles of infectious transmission, aerosol and droplet generation, as well as concepts of indoor airflow, will assist in the integration of new data on SARS‐CoV‐2 transmission and activities that can generate aerosol to best inform on the need for escalation or de‐escalation from current societal and institutional guidelines for protection during aerosol‐generating procedures.

13 November 2020 in Science Immunology
Verified
Journal Article
Closed access
LHLi-Yin Hung
Li-Yin Hung
YTYukinori Tanaka
Yukinori Tanaka
KHKarl Herbine
Karl Herbine
CPChristopher Pastore
Christopher Pastore
BSBrenal Singh
Brenal Singh
DHDeBroski Herbert
DeBroski Herbert
The pore-forming protein perforin-2 facilitates IL-33 release from dendritic cells.

15 June 2020 in International Forum of Allergy & Rhinology
Verified
Journal Article
Closed access
PDF file
MKMichael A. Kohanski
Michael A. Kohanski
JPJames N. Palmer
James N. Palmer
NCNoam A. Cohen
Noam A. Cohen

18 October 2020 in International Forum of Allergy & Rhinology
Verified
Journal Article
Closed access
PDF file
JDJennifer Douglas
Jennifer Douglas
ACAlyssa M. Civantos
Alyssa M. Civantos
TLTran B. Locke
Tran B. Locke
ASAuddie M. Sweis
Auddie M. Sweis
DHDenis Hadjiliadis
Denis Hadjiliadis
NANithin D. Adappa
Nithin D. Adappa